SYDNEY, July 10, 2024. Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce results from GBM-AGILE, a...

GATE 2025 application process is expected to begin from August 2024. Score obtained in exam will be valid for three years from declaration of results.

SYDNEY, July 10, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce...

In advance of its half-year results, Capricorn has provided an update on recent operations and the Group’s production guidance for 2024. The Company...

The prog legend will play an additional leg of US solo dates in 2024.

The latest on health innovation in Edmonton. API announces latest coaching program cohort; AHS joins envisAGE; Nature Digital Medicine publishes study...

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has successfully delivered the...

BlueNord has published its second quarter and first half results for 2024. The overarching strong production trend from previous years continued in...